NEW YORK, April 24, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced a major corporate restructuring with the objective of prioritizing and segregating its research and development efforts on a focused set of products in inflammatory disease and dermatology and strengthening its financial position.
In line with this prioritization, the Company’s Board of Directors (the “Board”) has authorized Dr. Daniel Teper to lead the Company’s oncology business within the Company’s Cytovia, Inc. subsidiary and to pursue a possible spin-off of Cytovia into a …
Read the full article at: http://finance.yahoo.com/news/immune-pharmaceuticals-announces-corporate-restructuring-123000585.html